Delivery is the mainstay of therapy for preeclampsia in the 37 weeks of gestation or occurrence of any of the following: repeated episodes of severe hypertension (blood pressure≥ 160/110 mmHg), despite maintenance treatment with 3 classes of antihypertensive agents, progressive thrombocytopenia, progressively abnormal renal or liver enzyme tests, pulmonary edema, abnormal neurological features, stroke, myocardial infarction, HELLP syndrome, eclampsia, suspected acute placental abruption or vaginal bleeding in the absence of placenta previa, abnormal fetal testing, fetal death, fetus without expectation for survival at the time of maternal diagnosis (lethal anomaly, extreme prematurity), or persistent reversed end-diastolic flow in the umbilical artery.

Delivery is the mainstay of therapy for preeclampsia in the 37 weeks of gestation or occurrence of any of the following:^[1]

• Repeated episodes of severe hypertension (blood pressure≥ 160/110 mmHg, despite maintenance treatment with 3 classes of antihypertensive agents)
• Progressive thrombocytopenia
• Progressively abnormal renal or liver enzyme tests
• Pulmonary edema
• Abnormal neurological features, such as severe intractable headache, repeated visual scotomata, convulsions,Visual disturbances, motor deficit, alteredsensorium
• Stroke
• Myocardial infarction
• HELLP syndrome (hemolysis, elevated liver enzymes, low platelet)
• Eclampsia
• Suspected acute placental abruption or vaginal bleeding in the absence of placenta previa
• Abnormal fetal testing
• Fetal death
• Fetus without expectation for survival at the time of maternal diagnosis (lethal anomaly, extreme prematurity)
• Persistent reversed end-diastolic flow in the umbilical artery